MARKET

TLRY

TLRY

TILRAY, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.07
-0.97
-10.73%
After Hours: 8.10 +0.03 +0.37% 19:59 12/01 EST
OPEN
9.00
PREV CLOSE
9.04
HIGH
9.11
LOW
8.03
VOLUME
28.23M
TURNOVER
--
52 WEEK HIGH
22.95
52 WEEK LOW
2.430
MARKET CAP
1.08B
P/E (TTM)
-1.8447
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Zacks · 13h ago
Looking Into Tilray's Return On Capital Employed
Tilray (NASDAQ: TLRY) reported Q3 sales of $51.41 million. Earnings fell to a loss of $31.35 million, resulting in a 57.91% decrease from last quarter. In Q2, Tilray brought in $50.41 million in sales but lost $74.49 million in earnings.Why ROCE Is Significant Changes in earnings and sales indicate shifts in Tilray's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Tilray posted an ROCE of -0.17%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on TLRYROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Tilray is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Tilray's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Insight Tilray reported Q3 earnings per share at $-0.02/share, which beat analyst predictions of $-0.21/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Tuesday's Pre-Market Session * Benzinga's Top Upgrades, Downgrades For November 16, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 1d ago
Aphria finalizes Sweetwater Brewing buy, shares up 7%
Aphria (APHA) has closed its takeover of privately held Sweetwater Brewing Company, one of the largest independent craft brewers, for ~$300M. The deal was announced on November 4.Shares are up 7% premarket
Seekingalpha · 1d ago
Aurora Cannabis inks supply deal for bulk dried flower with Cantek, shares down 6%
Aurora Cannabis (ACB) has entered into a strategic Supply Agreement with Cantek Holdings, one of Israel's leaders in the medical cannabis field. Under the terms of the Agreement, Aurora will
Seekingalpha · 6d ago
Should You Buy Marijuana Stocks As Biden Begins Transition?
Investor's Business Daily · 11/24 21:39
Tilray to exchange additional $72.9M convertible senior notes due 2023
Tilray ([[TLRY]] +15.4%) enters into privately negotiated exchange agreements with certain holders of its 5.00% Convertible Senior Notes due 2023. Pursuant to the exchange agreements, the company will exchange ~$72.9M in
Seekingalpha · 11/24 20:49
These Pot Stocks Hit Buy Zones As Biden Transition Lifts Industry Hopes
Investor's Business Daily · 11/24 16:55
Sundial Growers, DiaMedica Therapeutics leads healthcare gainers; Medigus, Graybug Vision among major losers
Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis (ACB) +19%, Lyra Therapeutics (LYRA) +19%, Tilray (TLRY) +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%, Arrowhead Pharmaceuticals (ARWR) -12%, Seres Therapeutics (MCRB) -10%.
Seekingalpha · 11/24 16:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLRY. Analyze the recent business situations of TILRAY, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLRY stock price target is 8.37 with a high estimate of 15.00 and a low estimate of 0.0000.
EPS
Institutional Holdings
Institutions: 302
Institutional Holdings: 18.09M
% Owned: 13.55%
Shares Outstanding: 133.53M
TypeInstitutionsShares
Increased
36
5.20M
New
60
-359.66K
Decreased
32
1.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
President/Chief Executive Officer/Director
Brendan Kennedy
Chief Financial Officer
Michael Kruteck
Corporate Executive
Katy Dickson
Chief Operating Officer
Jon Levin
Other
Andrew Pucher
Independent Director
Michael Auerbach
Independent Director
Christine Clare
Independent Director
Rebekah Dopp
Independent Director
Michael ..
Independent Director
Soren Schroder
Independent Director
Christine St.Clare
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TLRY
Tilray Inc is engaged in pharmaceutical sector. The Company is a supplier of cannabis products to pharmaceutical distributors. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Through its subsidiary, FHF Holdings Ltd (Manitoba Harvest) manufactures, markets and distributes hemp-based consumer products. The portfolio of Manitoba Harvest includes Hemp Hearts, Hemp Oil, Hemp Yeah! granola, Hemp Yeah! protein powder and Hemp Bliss milk. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tilray Inc stock information, including NASDAQ:TLRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLRY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLRY stock methods without spending real money on the virtual paper trading platform.